Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 3, showing 5 Applications out of 11 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s)

1.

ECCT/23/10/08   VALUE Placebo Film Study
    Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal Films (MATRIX-002)   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
View

2.

ECCT/17/09/04   A5354
    A5354       Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses   
Principal Investigator(s)
1. Brian Baker
Site(s) in Kenya
KISUMU CRS
 
View

3.

ECCT/17/11/01   MTN 034
    MTN 034   A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population   
Principal Investigator(s)
1. ESTHER MUMBI MAKANGA
Site(s) in Kenya
KISUMU CRS
 
View

4.

ECCT/16/06/02   A5263: A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings
     A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   
Principal Investigator(s)
1. Vincent Oliver Otieno
Site(s) in Kenya
1. Kisumu CRS (Kisumu county)
 
View

5.

ECCT/20/04/03   518 & 525-SHAN6â„¢
    Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants.    Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age   
Principal Investigator(s)
1. Bernhards Ogutu
2. Godfrey Allan Otieno
3. Videlis Nduba
4. Lucy Chepkurui Koech
5. samuel Gurrion Ouma
6. Janet Oyieko
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county)
5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county)
6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county)
7. CRDR_Siaya Annex(Back-up site) (Siaya county)
 
View